The identification of oncogenic BCR fusion proteins emphasizes the importance of determining malignant genetic alterations in patients and stresses the need for the development of personalized medical treatments for hematopoietic cancers. This evidence concerns the gene BCR and hematopoietic and lymphoid cell neoplasm.